Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company Plc (NYSE: PRGO) is a global provider of quality, affordable self-care products and over-the-counter health solutions. This dedicated news hub offers investors and industry professionals centralized access to official announcements, financial disclosures, and market developments.
Track Perrigo's strategic initiatives through verified press releases covering earnings results, product innovations, regulatory milestones, and partnership announcements. Our curated collection provides essential insights into the company's operations across key markets in North America, Europe, and global consumer health sectors.
Discover updates on Perrigo's store-brand leadership, branded OTC developments, and manufacturing advancements. The resource serves as a reliable reference for monitoring the company's progress in delivering accessible healthcare solutions through major retail partnerships and direct-to-consumer channels.
Bookmark this page for streamlined access to Perrigo's latest business updates, including analysis of market positioning in consumer self-care categories and operational efficiency programs. Stay informed about one of the OTC sector's most established innovators through verified, up-to-date information sources.
Perrigo (NYSE: PRGO) reported third-quarter 2025 results on Nov. 5, 2025 showing Q3 net sales of $1.04 billion (down 4.1% YoY) and adjusted operating income of $173 million. Q3 adjusted EPS was $0.80 (vs. $0.81 prior year). Year-to-date 2025 adjusted EPS rose to $1.97 (+20.9% reported; +27.0% organically) and adjusted operating income was $455 million (+9.8%). The company achieved store-brand share gains in 5 of 7 OTC categories and six consecutive months of store-brand volume share gains. Perrigo initiated a strategic review of its Infant Formula business, continues a review of Oral Care, and expects to close the Dermacosmetics sale in Q1 2026. Fiscal 2025 outlook updated to net sales -2.5% to -3.0% and adjusted EPS $2.70–$2.80 reflecting industry dynamics and soft OTC consumption.
Perrigo (NYSE: PRGO) announced on November 5, 2025 that it is initiating a strategic review of its infant formula business to assess a full range of alternatives aligned with its Three-S plan (Stabilize, Streamline, Strengthen).
The review will reconsider a prior $240 million investment and focus on accelerating cash flows and optimizing portfolio impact. The infant formula business is expected to generate ~$360 million in 2025, ~90% of Perrigo's Nutrition category and under 10% of Perrigo's annual net sales. No decisions or timetable have been set; Perrigo will continue supplying product during the review.
Perrigo (NYSE: PRGO) announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled for one-on-one investor meetings at the Jefferies Miami Consumer Conference on Tuesday, November 18, 2025.
The release describes Perrigo as a pure-play consumer health company with leading OTC brands and notes investor contacts and a forward-looking statements caution directing readers to the company's SEC filings for risks and financial information.
Perrigo (NYSE: PRGO) announced a quarterly dividend of $0.290 per share, payable on December 16, 2025 to shareholders of record on November 28, 2025. The declaration signals a scheduled cash distribution to shareholders and provides exact record and payment dates for investors.
For more information on Perrigo's business and financial disclosures, investors are directed to the company's SEC filings and investor relations resources.
Perrigo (NYSE: PRGO) announced it will release third quarter 2025 financial results on Wednesday, November 5, 2025 and host a conference call at 8:30 A.M. EST.
The call will stream live via webcast in the investor relations section at perrigo.investorroom.com/events-webcasts and is accessible by phone (US: 800-836-8184; International: 646-357-8785) with reference ID 03742. A taped replay will be available beginning ~12:00 P.M. EST on November 5 through midnight on November 12, 2025 (replay dial 888-660-6345 or International 646-517-4150; access code 03742#).
Company background: Perrigo is a self-care products company with leading store-brand and branded portfolios including Opill, Mederma, Compeed, EllaOne, and Jungle Formula.
Perrigo (NYSE: PRGO) announced on October 9, 2025 a brand collaboration between Opill and Chillhouse called "Opill and Chill". The partnership launches three limited-edition press-on nail sets — Same Time Tomorrow, OTC Chill and In Control — with online and retail availability.
For every Opill-themed Chill Tips set sold, Perrigo will donate one pack of Opill to NY Birth Control Access Project for statewide distribution. The collaboration includes an in-person activation at Chillhouse Soho in NYC on Oct. 9, 2025 from 1–5 PM ET, with free applications for the first 200 guests and live conversations on reproductive health.
Products are available at Chillhouse.com and Amazon while supplies last.
Perrigo (NYSE:PRGO), a leading self-care company, announced that its President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will participate in one-on-one investor meetings at the Barclays Global Consumer Staples Conference on September 3rd, 2025.
The company, with over a century of experience, specializes in over-the-counter (OTC) self-care products in North America and Europe. Their business model combines store brand private label offerings with branded products including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.
Perrigo (NYSE:PRGO) reported Q2 2025 financial results with net sales of $1.06 billion, down 0.9% year-over-year. The company's adjusted EPS reached $0.57, up 7.5% from the previous year, despite challenging market conditions. The company is executing its 'Three-S' strategic plan (Stabilize, Streamline, and Strengthen) and recently announced the sale of its Dermacosmetics business.
Key financial metrics include adjusted operating income of $135 million (down 2.9%) and an adjusted operating margin of 12.8% (down 30 basis points). The company maintained its full-year 2025 adjusted EPS target range of $2.90 - $3.10, although net sales growth is expected to be at the lower end of guidance due to infant formula industry dynamics and market consumption trends.
Project Energize, launched in Q1 2024, has achieved gross annual savings of $159 million with reinvestment of $27 million, targeting total annualized pre-tax savings of $140-170 million by the end of 2026.
Perrigo (NYSE: PRGO), a leading global self-care company, has declared a quarterly dividend of $0.290 per share. The dividend will be payable on September 16, 2025, to shareholders of record on August 29, 2025.
The company, with over a century of experience, specializes in over-the-counter (OTC) self-care products in North America and Europe. Perrigo's business model combines store brand private label offerings with leading brands including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.
[ "Consistent dividend payment demonstrates financial stability", "Strong market presence with century-long experience in self-care products", "Diversified portfolio combining private label and branded products" ]Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12th at 9:00 AM EDT.
The company, a pioneer in the over-the-counter (OTC) self-care market, has over a century of experience providing health and wellness solutions in North America and Europe. Perrigo's business model combines store brand private label offerings with leading brands including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
